2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 31

Interaction of FGF-8 and TNF-a in the Regulation of BMP-Induced Osteoblast Differentiation
Abstract Number: 1959

Interaction of PDE4 and β-Arrestin Reverses Anti-Inflammatory Effects of Catecholamine-Producing Cells in Chronic Arthritis Via Adrenoceptor Switching from Gαs to GαI Signalling
Abstract Number: 2161

Interest of Systematic Lyme Serology in Context of Recent Onset Arthritis
Abstract Number: 2760

Interferon Alfa-Associated Depression in Patients with Behçet’s Syndrome
Abstract Number: 1619

Interferon Dysregulation in an Academic SLE Cohort Is Associated with Distinct Signaling Differences in Blood Neutrophils Versus PBMCs
Abstract Number: 1645

Interferon Gene Signature Expression and Serological Differences in Japanese and Non-Japanese SLE Patients
Abstract Number: 662

Interferon Regulatory Factor-5 Promotes Disease in the MRL/Lpr Mouse Model of Lupus
Abstract Number: 1625

Interferon Stimulates Transglutaminase Activity on Human Monocytes and Their Microparticles
Abstract Number: 872

Interferon-α and Angiogenic Dysregulation in Pregnant Lupus Patients Destined for Preeclampsia
Abstract Number: 1901

Interferon-γ (IFNγ) in Macrophage Activation Syndrome (MAS) Associated with Systemic Juvenile Idiopathic Arthritis (sJIA). High Levels in Patients and a Role in a Murine MAS Model
Abstract Number: 884

Interleukin 6 Does Not Upregulate Pro Inflammatory Cytokine Expression in an Ex-Vivo Model of Giant Cell Arteritis
Abstract Number: 2237

Interleukin-1 Dual-Variable Domain Immunoglobulin Reduces Multiple Inflammatory Markers in Knee Osteoarthritis Patients
Abstract Number: 2876

Interleukin-10 Receptor Blockade during Lcmv Infection Results in Macrophage Activation Syndrome-like Disease in Mice
Abstract Number: 834

Interleukin-18 (IL-18) As a Biomarker for Diagnosis and Evaluation of Disease Activity in Patients with Adult Onset Still’s Disease and Systemic Onset Juvenile Idiopathic Arthritis
Abstract Number: 1039

Interleukin-20 Is Triggered By TLR Ligands and Associates with Rheumatoid Arthritis Disease Activity

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].